论文部分内容阅读
正电子发射断层(PET)显像可以活体、无创反映疾病的特征分子改变,如利用~(18)氟-脱氧葡萄糖(~(18)F-FDG)反映肿瘤的葡萄糖代谢,以及利用~(18)氟-硝基咪唑(~(18)F-FMISO)反映肿瘤的乏氧状态等。质谱成像(MSI)不需要标记和复杂准备,可以离体检测到成百上千种分子在病灶内的精确分布信息,但这些分子的功能往往不易明确。本研究利用BALB/c裸鼠4T1乳腺癌肿瘤模型,将PET显像和电喷雾MSI结合,通过图像对比和统计软件分析,分别找到了与PET糖代谢图像和乏氧图像匹配的系列分子,通过查找人类代谢组数据库,初步确定了这些分子的组成。基于以上,本研究初步证实了PET显像和质谱成像互补结合寻找特征分子标志物的可行性。
Positron emission tomography (PET) imaging can be used to identify the characteristic molecular changes of the disease in vivo and noninvasively, such as ~ (18) fluorodeoxyglucose (~ (18) F-FDG) ) Fluoro-nitroimidazole (~ (18) F-FMISO) reflects the tumor hypoxia status. Mass spectrometry imaging (MSI) does not require labeling and sophisticated preparation to detect the precise distribution of hundreds or even thousands of molecules in the lesion in vitro, but the function of these molecules is often not well understood. In this study, BALB / c nude mice model of 4T1 breast cancer was used to combine PET imaging and electrospray MSI. Through image comparison and statistical software analysis, a series of molecules matching PET glucose metabolism images and hypoxia images were found respectively. Find human metabolomics database, initially identified the composition of these molecules. Based on the above, this study initially confirmed the feasibility of searching for molecular markers by complementary combination of PET imaging and MS imaging.